ContraFect Corp. Stock
-
Your prediction
Pros and Cons of ContraFect Corp. in the next few years
Pros
Cons
Performance of ContraFect Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ContraFect Corp. | - | - | - | - | - | - | - |
| Vaxart Inc. | -1.230% | -13.095% | -17.663% | 27.911% | 57.680% | -81.808% | - |
| Jaguar Health Inc. | -2.710% | 41.363% | 125.970% | 93.606% | 0.265% | -99.937% | - |
| aTyr Pharma Inc | -3.900% | -0.645% | -14.444% | -10.465% | 19.380% | -48.667% | -76.744% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, the financials of ContraFect, a company within the Biotechnology & Medical Research industry, seem to show a financially struggling business with significant challenges in its revenue and cash flow generation. The net income has consistently been negative over the past few years, and the company's total assets have declined. However, it's essential to remember that biotechnology companies often have substantial upfront costs and investments, with profitability and returns on investments taking years to materialize.
Pros: ** 1. **Notable increase in research and development expenses: In 2022, ContraFect's research and development expenses increased to $44,738,000 from $35,508,000 in 2021 and $22,613,968 in 2020. This increase in R&D could potentially result in new products and technologies that can drive future revenue growth for the company.
Decrease in short-term debt: The company's short-term debt decreased from $657,000 in 2021 to $671,000 in 2022, indicating a slightly healthier financial position with fewer immediate debt obligations.
